                         SEQUENCE LISTING

<110>  University of Copenhagen
 
<120>  Inhibitors of PICK1 and uses thereof

<130>  P4997PC00

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  DAT-C5, 5 C-terminal residues of human dopamine transporter

<400>  1

His Trp Leu Lys Val 
1               5   


<210>  2
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  Variants of DAT-C5


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X is a proteogenic or non-proteogenic amino acid, preferably H, 
       L, I, or          

A; or is absent

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is a proteogenic or non-proteogenic amino acid, preferably W, 
       or F; or is absent

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  is a proteogenic or non-proteogenic amino acid, preferably L, V, 
       I, F, A, or Y

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  is a proteogenic or non-proteogenic amino acid, preferably K, or 
       R

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  is V, I or C

<400>  2

Xaa Xaa Xaa Xaa Xaa 
1               5   


<210>  3
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  Variants of DAT-C5


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is H, L, I, A; or is absent

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  is W, F; or is absent

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X3  is L, V, I, F, A, or Y

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  is K or R

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  is V, I or C

<400>  3

Xaa Xaa Xaa Xaa Xaa 
1               5   


<210>  4
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  Variants of DAT-C5


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is H, L, I, or A

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  is W or F

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  is L, V, I, F, A, or Y

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  K or R

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  is V, I or C

<400>  4

Xaa Xaa Xaa Xaa Xaa 
1               5   


<210>  5
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  Variants of DAT-C5


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is H, I, or A

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  is W or F

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  is L, I or V

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  is K or R

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  is V or C

<400>  5

Xaa Xaa Xaa Xaa Xaa 
1               5   


<210>  6
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  Variants of DAT-C5


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is H or A

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  is W

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  is L, I or V

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  is K or R

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  is V

<400>  6

Xaa Xaa Xaa Xaa Xaa 
1               5   


<210>  7
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  CPP sequence (TAT) derived from the human immunodeficiency 
       virus-type 1 (HIV-1) Tat protein

<400>  7

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   10      


<210>  8
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  TAT fragment 1


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  is a proteogenic or non-proteogenic amino acid, preferably H, L, 
       I, or A

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  is a proteogenic or non-proteogenic amino acid, preferably W, or 
       F

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  is a proteogenic or non-proteogenic amino acid, preferably L, V, 
       I, F, A, or Y

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  is a proteogenic or non-proteogenic amino acid, preferably K, or 
       R

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  is V, I or C

<400>  8

Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   


<210>  9
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  TAT fragment 2

<400>  9

Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro 
1               5                   10      


<210>  10
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  Retroinverso-D-TAT


<220>
<221>  MISC_FEATURE
<222>  (1)..(9)
<223>  D-amino acid

<400>  10

Arg Arg Arg Gln Arg Arg Lys Lys Arg 
1               5                   


<210>  11
<211>  8
<212>  PRT
<213>  artificial sequence

<220>
<223>  Polyarginine peptide

<400>  11

Arg Arg Arg Arg Arg Arg Arg Arg 
1               5               


<210>  12
<211>  16
<212>  PRT
<213>  artificial sequence

<220>
<223>  16 a.a. sequence (PNT), derived from Antennapedia homeodomain 
       (DHAntp) from Drosophilia, belonging to the third  -helix of the 
       DHAntp, corresponding to residue 43-58

<400>  12

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


<210>  13
<211>  27
<212>  PRT
<213>  artificial sequence

<220>
<223>  Transportan10 (TP10), truncated analogue of Transportan, 
       synthesized by deletion of six a.a. from the N-terminus

<400>  13

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu 
1               5                   10                  15      


Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 
            20                  25          


<210>  14
<211>  18
<212>  PRT
<213>  artificial sequence

<220>
<223>  "Model of Amphipathic Helix" (MAP), an artificial sequence and 
       designed to have cell-penetrating properties

<400>  14

Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys 
1               5                   10                  15      


Leu Ala 
        


